Skip to main content
. Author manuscript; available in PMC: 2017 Sep 5.
Published in final edited form as: Leuk Res. 2014 Sep 10;38(11):1332–1341. doi: 10.1016/j.leukres.2014.09.001

Figure 5. SGI-110 treatment induces recognition by NY-ESO-1-specific, HLA compatible CD8+ T cells.

Figure 5

A–D) KG1a cells pretreated with SGI-110, DAC, or AZA at the concentrations shown were cultured with HLA-B35 restricted NY-ESO-1-specific CD8+ T cells. Expression of CD107a/b, IFN-γ, TNF-α, and granzyme B in HLA-B35/NY-ESO-194–102 tetramer+ CD8+ T cells was assessed by flow cytometry. All experiments were repeated three times. E) Representative flow plots for vehicle and SGI-110- 1 μM treated KG1a cells* p<0.05 vs. vehicle, **p<0.05 vs. DAC, ***p<0.05 vs. AZA.